drugset / Trial / NCT04102800
Benralizumab Exacerbation Study
Phase 4
Completed
157 enrolled
NHS Greater Glasgow and Clyde
AstraZeneca · collabBosch Healthcare Solutions GmbH · collabInHealthcare · collabQueen's University, Belfast · collabUniversity of Glasgow · collabUniversity of Leicester · collabUniversity of Plymouth · collabVitalograph · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an exploratory study, the focus of which is to understand the nature of asthma exacerbations that occur despite open label benralizumab therapy in severe eosinophilic asthma.
Timeline
- Start
- 2019-09-30
- Primary completion
- 2024-02-22
- Completion
- 2024-04-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benralizumab | Monoclonal antibody | 30 mg | Subcutaneous |